TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Total Radioactivity Recovery Rate of Evobrutinib, Total Radioactivity and its Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Evobrutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-rated measures of mental health symptoms and distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Linkage to care for ART-eligible patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Retention in care for TB patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Linkage and retention in care for ART-eligible HIV/TB co-infected patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes of Salivary Alpha-amylase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: renal allograft function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Economic Outcome Measure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Quality of Life Outcome Measure
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Geometric Mean Titers (GMTs) Against Each Dengue Virus Serotype 28 Days After Last CYD Dengue Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers Against Each Dengue Virus Serotype 1 Year After Last CYD Dengue Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers Against Each Dengue Virus Serotype After the Third Dose of CYD Dengue Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of DBS
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Plasma Itraconazole Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time Zero to 24 Hours Post-dose Observed Plasma Itraconazole Concentration (AUC[0-24])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Inhibitory Concentration (MIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete recovery rate of EPSSBO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain free rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects whose baseline score on the subjective FCST correctly estimates the baseline MHST score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relationship between hemoglobin (hgb) response and change in functional capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Lens Centration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post Blink Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Severe Neutropenia in Cycle 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: AUClast of fenofibric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of fenofibric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUClast of pitavastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of pitavastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Physical Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Psychological Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: evolution of wound surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: clinical efficacy (cure or marked improvement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean total bone volume changes (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 28 day ICU and hospital mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change in Urine Gb3 Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of time with brain temperature within target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of tipping of the lower second permanent molars
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post Dural Puncture Headaches
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expectorated sputum volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Absence of stoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional outcome of primary vitrectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anatomical outcome of primary vitrectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the levels of swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the levels of chewing difficulties
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum Tolerated Dose (MTD) of topotecan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forced expiratory volume % predicted values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in MDS-UPDRS III motor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in past-month drug use days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in use of relationship safety behaviors and referral resources for IPV
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in child behavior problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hoehn & Yahr (H&Y) stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parkinson's Disease questionnaire (PDQ-39) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Accuracy of BCI Typing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowering of systolic office blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lowering of diastolic office blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Symptoms of Attention Deficit Hyperactive Disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of rehabilitation services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Heel pain composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Roles and Maudsley Score
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Days Adherent to Sunscreen Use
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in weight following weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in brain kappa opioid receptor occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neural activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients with controlled blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Weekly Percentage of Heavy Drinking Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days with asthma symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First bowel sound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in re-operation rate
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of surgery for isolated lateral ankle fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: summation of scar scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Objective response (confirmed and unconfirmed complete and partial responses)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall antitumor assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Blood Culture Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With All-cause Deaths up to 30 Days After Study Treatment Discontinuation
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Systolic and Diastolic Arterial Blood Pressure (BP) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) up to 30 Days After Study Treatment Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Modified Ranking Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Procedural Pain Intensity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Sufentanil and Ketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of Sufentanil and Ketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Plasma Concentrations (Tmax) Sufentanil and Ketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total and individual fecal bile acid excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total fecal excretion of short chain fatty acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fecal microbial population and community from stool collection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Average number of steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in ocular rigidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CIS (checklist individual strength)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sexual Function Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ctDNA alterations to progression disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) on Cycle 1 Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Clinical Benefit Response (CBR) Based on the Extramural Review Committee Assessment in Recommended Dose Group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thymic naïve T-cell production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of subjects with electrographic seizures
Endpoint domain: Adverse events/effects
Primary endpoint: Patients' Immune Response Assessed by Delayed Type Hypersensitive (DTH) Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Systemic Immune Response: T-cell Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunological Activation in Tumour Mass by Assessing Number of Patients With Increased Intra-tumoural Lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: time to eating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiological evidence of resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effectiveness of parent's training program
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Presence of MRSA colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Personal attitudes toward intimate partner violence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived norms about intimate partner violence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Completion of continuum of care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Mood scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of grade 2 or higher acute toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in iron absorption of stable isotope tracers at week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in iron incorporation of stable isotope tracers at week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in iron absorption of stable isotope tracers at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in iron incorporation of stable isotope tracers at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cuff sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delay in chest compressions during resuscitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: End systolic left ventricular diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Ocular Itching Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Hs-C Reactive Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Remission Induction Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants Experiencing a Dose-limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to progression to secondary AML
Endpoint domain: Mortality/survival
Primary endpoint: SODA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean UAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: E/E'(Unitless)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anti-rotavirus IgA antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Functional brain networks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Objective vocal cord mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnosis performance of 18-FDG PET-CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of sputum weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Extended Glances Away From Roadway During Driving Simulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard Deviation of Lateral Position During Driving Simulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COVID-19 vaccine effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Brain excitation and inhibition response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain activation response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain connectivity response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Autism Behavior Checklist (ABC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivary IgA and Salivary Cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WeeFIM measurement of child's functional abilities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: initiation of buprenorphine treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC OA Pain Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in amyloid deposit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cholesterol Uptake Capacity (CUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: NIHSS Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in the Numerical Rating Pain Scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Long-term Disease-free Survival (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: clinical efficacy scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Admission to Intensive Care Unit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Drug concentrations in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Lipid make-up alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Morphine requirement
Endpoint domain: Adverse events/effects
Primary endpoint: Typical daptomycin clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Typical daptomycin volume of distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed up And Go Test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the NAFLD fibrosis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Serum Concentration of CNTO 328
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in mean systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hepatic elasticity measured by FIBROSCANN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free Survival for at Least 6 Months (PFS-6)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Adverse Events and Severe Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, grade ≥3 (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Work-related sense of coherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Seroprevalence of antibodies to hepatitis E virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: pH measurement of the tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuous Abstinence at 3-months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With Bone-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in fitness (peak VO2mL/kg/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Exhibiting Desaturation >5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative consumption of morphine
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvements in social skills as assessed by Social Responsiveness Scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Improvements in social skills as assessed by Social Skills Improvement System
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Improvements in social skills as assessed by the Project Rex Parent Survey
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Pulmonary arterial systolic, diastolic and mean pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SpO2 (Pulsed oxygen saturation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: heavy drinking days per week change
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Patient satisfaction with care pathways
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality of Life measures
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: retention rate
Endpoint domain: Life impact
Endpoint subdomain: Role functioning